Immune checkpoint inhibitors (ICIs) block inhibitory molecules, such as cytotoxic T-
lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), or its …

The immune-cell origin of hematologic malignancies provides a unique avenue for the
understanding of both the mechanisms of immune responsiveness and immune escape …

Adverse events (AEs) related to the use of immune checkpoint inhibitor (ICI) therapy are
defined as immune-related (IR) AEs (irAEs). irAEs are graded according to the Common …

Immune checkpoint inhibitors (ICIs) have increasingly been the mainstay of treatment for
numerous malignancies. However, due to their association with autoimmunity, ICIs have …

Introduction: An increasing number of immune-related adverse events (irAEs) induced by
immune checkpoint inhibitors (ICIs) have been reported during clinical treatment. We aimed …

Background: Acquired hemophagocytic lymphohistiocytosis (HLH) is a rare but potentially
fatal condition characterized by hyperactivation of macrophages and cytotoxic lymphocytes …

Introduction Immune checkpoint inhibitors (ICI) are associated with unique immune-related
adverse events (irAEs). Immune-related thrombocytopenia (irTCP) is an understudied and …

Simple Summary Data on immune checkpoint inhibitor (ICI)-related cytopenias are scarce.
The aim of the study was to further characterize grade≥ 2 ICI-related cytopenias using the …

Immunotherapy has revolutionized the cancer treatment landscape by opening up novel
avenues for intervention. As the use of immune checkpoint inhibitors (ICIs) has exponentially …

Despite the extraordinary success of immune checkpoint inhibitors (ICIs) in cancer
treatment, their use is associated with a high incidence of immune-related adverse events …